Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAT Phathom Pharmaceuticals

Trading 05-15 15:44:58 EDT

10.38

-0.01

-0.10%

High10.68	Low10.10	Vol265.11K
Open10.43	D1 Closing10.39	Amplitude5.58%
Mkt Cap607.48M	Tradable Cap449.09M	Total Shares58.52M
T/O2.75M	T/O Rate0.61%	Tradable Shares43.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PHAT","market":"US","secType":"STK","nameCN":"Phathom Pharmaceuticals","latestPrice":10.38,"timestamp":1715802294086,"preClose":10.39,"halted":0,"volume":265109,"delay":0,"floatShares":43264483,"shares":58524082,"eps":-4.460393,"marketStatus":"Trading","change":-0.01,"latestTime":"05-15 15:44:58 EDT","open":10.43,"high":10.68,"low":10.1,"amount":2752435.338302,"amplitude":0.055823,"askPrice":10.38,"askSize":125,"bidPrice":10.36,"bidSize":598,"shortable":3,"etf":0,"ttmEps":-4.460393,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1715803200000},"marketStatusCode":2,"adr":0,"listingDate":1571976000000,"exchange":"NASDAQ","adjPreClose":10.39,"postHourTrading":{"tag":"盘后","latestPrice":10.39,"preClose":10.39,"latestTime":"19:43 EDT","volume":9040,"amount":93922,"timestamp":1715730220948},"volumeRatio":0.378283},"requestUrl":"/m/hq/s/PHAT","defaultTab":"news","newsList":[{"id":"2435317446","title":"Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2435317446","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2435317446?lang=en_us&edition=fundamental","pubTime":"2024-05-15 12:00","pubTimestamp":1715745600,"startTime":"0","endTime":"0","summary":"First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA in Non-Erosive Reflux Disease (NERD)1New research on Erosive gastroesophageal reflux disease (GERD) demonstrating","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/15/2882383/0/en/Phathom-Pharmaceuticals-to-Present-VOQUEZNA-vonoprazan-Data-at-DDW-2024-Annual-Meeting.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434946859","title":"Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434946859","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434946859?lang=en_us&edition=fundamental","pubTime":"2024-05-10 21:16","pubTimestamp":1715346963,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today. The company’s shares cl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-remains-a-buy-on-phathom-pharmaceuticals-phat?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-remains-a-buy-on-phathom-pharmaceuticals-phat?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434823010","title":"Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), ACELYRIN, INC. (SLRN) and Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434823010","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434823010?lang=en_us&edition=fundamental","pubTime":"2024-05-10 00:20","pubTimestamp":1715271611,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phathom Pharmaceuticals (PHAT – Research Report), ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phathom-pharmaceuticals-phat-acelyrin-inc-slrn-and-moderna-mrna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phathom-pharmaceuticals-phat-acelyrin-inc-slrn-and-moderna-mrna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434201481","title":"Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2434201481","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2434201481?lang=en_us&edition=fundamental","pubTime":"2024-05-09 21:15","pubTimestamp":1715260504,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals, Inc.  came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to loss of $0.89 per share a year ago. These figures are adjusted for non-recurring items.Phathom Pharmaceuticals , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.91 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 30.73%. This compares to zero revenues a year ago.Phathom Pharmaceuticals shares have added about 10.6% since the beginning of the year versus the S&P 500's gain of 8.8%.While Phathom Pharmaceuticals has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the to","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nxwFIPS2ImeTQYZMYlnAgg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nxwFIPS2ImeTQYZMYlnAgg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phathom-pharmaceuticals-inc-phat-reports-131504755.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434091835","title":"Phathom Pharmaceuticals Non-GAAP EPS of -$1.11 beats by $0.06, revenue of $1.91M misses by $0.23M","url":"https://stock-news.laohu8.com/highlight/detail?id=2434091835","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434091835?lang=en_us&edition=fundamental","pubTime":"2024-05-09 20:05","pubTimestamp":1715256328,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals press release : Q1 Non-GAAP EPS of -$1.11  beats by $0.06. Revenue of $1.91M  misses by $0.23M. As of March 31, 2024, cash and cash equivalents were $322.2 million. Up to an additional $150 million is also available under the Company’s term loan with Hercules.  Based on its current cash resources and operating plan, including expected product revenues, and the funds potentially available under its existing term loan, the Company believes it will have sufficient capital to fund operations through the end of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4103611-phathom-pharmaceuticals-non-gaap-eps-of-1_11-beats-0_06-revenue-of-1_91m-misses-0_23m","is_publish_highlight":false,"gpt_icon":0},{"id":"2434099255","title":"Phathom Pharmaceuticals Q1 2024 GAAP EPS $(1.42) Misses $(1.28) Estimate, Sales $1.912M Miss $2.047M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2434099255","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2434099255?lang=en_us&edition=fundamental","pubTime":"2024-05-09 20:01","pubTimestamp":1715256117,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(1.42) per share which missed the analyst consensus estimate of $(1.28) by 10.94 percent. This is a 59.55 percent decrease over losses of $(0.89) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38728745/phathom-pharmaceuticals-q1-2024-gaap-eps-1-42-misses-1-28-estimate-sales-1-912m-miss-2-047m-estimat","is_publish_highlight":false,"gpt_icon":0},{"id":"2434999990","title":"BRIEF-Phathom Pharmaceuticals Q1 Net Income USD -82.852 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2434999990","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434999990?lang=en_us&edition=fundamental","pubTime":"2024-05-09 20:00","pubTimestamp":1715256046,"startTime":"0","endTime":"0","summary":"May 09 (Reuters) - Phathom Pharmaceuticals Q1 basic EPS USD -1.42.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432187249","title":"Phathom a buy at Stifel on new heartburn therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2432187249","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432187249?lang=en_us&edition=fundamental","pubTime":"2024-05-04 02:31","pubTimestamp":1714761113,"startTime":"0","endTime":"0","summary":"Stifel has initiated Phathom Pharmaceuticals  at buy citing the company's acid-reducing therapy Voquezna  as a drug that could potentially become a new standard of care. The firm has a target price of $24 . Analyst Annabel Samimy noted that Voquezna, which is a potassium-competitive acid blocker, the first drug with a new mechanism of action to treat erosive gastroesophageal reflux disease and H. pylori infection. Proton-pump inhibitors are the current standard of care. She praised potassium-competitive acid blockers' \"rapid, superior, and durable activity.\" Samimy added that providers are receptive to Voquezna given that many patients try multiple PPI medications without success. In addition, payers have been covering the drug with \"relatively modest restrictions.\" Sales of Voquenza in Japan have reached around $850M annually, an indication, according to Samimy, that there is an unmet need to drugs to treat GERD and similar conditions. Voquenza could see an additional sales boost in J","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185078746/image_185078746.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185078746/image_185078746.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4099896-phathom-buy-stifel-new-heartburn-therapy","is_publish_highlight":false,"gpt_icon":0},{"id":"2432972504","title":"Buy Rating Affirmed for Phathom Pharmaceuticals on V oquezna’s Promising Market Trajectory","url":"https://stock-news.laohu8.com/highlight/detail?id=2432972504","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432972504?lang=en_us&edition=fundamental","pubTime":"2024-05-03 21:05","pubTimestamp":1714741526,"startTime":"0","endTime":"0","summary":"Needham analyst Joseph Stringer has maintained their bullish stance on PHAT stock, giving a Buy rating yesterday. Joseph Stringer has given his Buy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-phathom-pharmaceuticals-on-v-oqueznas-promising-market-trajectory?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-phathom-pharmaceuticals-on-v-oqueznas-promising-market-trajectory?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2431149855","title":"Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2431149855","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2431149855?lang=en_us&edition=fundamental","pubTime":"2024-04-29 12:00","pubTimestamp":1714363200,"startTime":"0","endTime":"0","summary":"Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., April  29, 2024  (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/29/2871202/0/en/Phathom-Pharmaceuticals-to-Report-First-Quarter-2024-Financial-Results-and-Provide-Business-Update-on-Thursday-May-9-2024.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430769432","title":"Buy Rating Justified by Strong Market Acceptance of Phathom Pharmaceuticals’ V oquezna","url":"https://stock-news.laohu8.com/highlight/detail?id=2430769432","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2430769432?lang=en_us&edition=fundamental","pubTime":"2024-04-26 20:25","pubTimestamp":1714134340,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Stringer from Needham maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report), with a price ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-justified-by-strong-market-acceptance-of-phathom-pharmaceuticals-v-oquezna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-justified-by-strong-market-acceptance-of-phathom-pharmaceuticals-v-oquezna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2429591571","title":"SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT","url":"https://stock-news.laohu8.com/highlight/detail?id=2429591571","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2429591571?lang=en_us&edition=fundamental","pubTime":"2024-04-22 15:30","pubTimestamp":1713771000,"startTime":"0","endTime":"0","summary":"Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour DUBLIN and OXFORD, England, April 22, 2024 /PRNewswire/ -- SynOx Therapeutics Limited , the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m Series B financing. The financing was co-led by Forbion, HealthCap and new investor Bioqube Ventures.The proceeds will be used to generate registrational Phase 3 clinical and CMC data for emactuzumab, SynOx's potentially best-in-class CSF-1 inhibiting monoclonal antibody  for the treatment of Tenosynovial Giant Cell Tumour .Ray Barlow, Chief Executive Officer of SynOx Therapeutics, said: \"This is a transformational time for SynOx. This substantial funding will allow us to generate registrational data for emactuzumab in TGCT. As a highly effective, next-generation therapy with a short treatment cycle, rapid onset","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23092862","is_publish_highlight":false,"gpt_icon":0},{"id":"2428069335","title":"MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2428069335","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2428069335?lang=en_us&edition=fundamental","pubTime":"2024-04-20 03:03","pubTimestamp":1713553380,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from April 11 through April 17, 2024. Source: VerityData. MasterCraft Boat Holdings Coliseum Capital Management increased its stake in the boat manufacturer to 2,224,284 shares. Coliseum purchased 222,873 MasterCraft Boat Holdings shares from March 14 through April 11 at prices ranging from $20.66 to $22.05 apiece. Following the purchases, Coliseum now owns 13.1% of MasterCraft Boat Holdings' outstanding stock. Shares have lost roughly 5% year to date.Following the sales, Insight continues to own 8.2% of SentinelOne's outstanding stock. Shares of SentinelOne have lost roughly 13.1% during the year.Following the sales, Takeda owns 4.8% of Phathom Pharmaceuticals' outstanding stock, below the 5% thresho","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2428698198","title":"Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2428698198","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2428698198?lang=en_us&edition=fundamental","pubTime":"2024-04-20 02:51","pubTimestamp":1713552660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 19, 2024 14:51 ET (18:51 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2428663969","title":"12 Most Shorted Stocks in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2428663969","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2428663969?lang=en_us&edition=fundamental","pubTime":"2024-04-19 23:02","pubTimestamp":1713538961,"startTime":"0","endTime":"0","summary":"In this article, we will take a detailed look at the12 Most Shorted Stocks in 2024.For a quick overview of such stocks, read our article 5Most Shorted Stocks in 2024.), but investors often find themselves thanking these companies for doing the often back-breaking and excruciating research that is required to unfold financial irregularities, fraud, misconduct and mismanagement in corporate America. Short sellers are always in the news as they remain on the lookout for their next prey. Consider Hindenburg Research for example, the activist short-selling firm led by Nathan Anderson. Hindenburg made headlines last year when it went after companies of billionaires Carl Icahn and Gautam Adani. The power of Hindenburg’s attack could be gauged from the fact that Adani’s empire of businesses lost over $100 billion in market value while his personal worth tanked by $80 billion. Adani has since rebounded, but the billionaire’s conglomerate was surely jolted to the core by the short-selling firm.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/iyCAEUcVIfefu4M0txjNrg--~B/aD0xNDQwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/9fea791571ceb7865c772a2bc987ac30","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/iyCAEUcVIfefu4M0txjNrg--~B/aD0xNDQwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/9fea791571ceb7865c772a2bc987ac30"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/12-most-shorted-stocks-2024-150241603.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427461387","title":"Gyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2427461387","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2427461387?lang=en_us&edition=fundamental","pubTime":"2024-04-13 19:21","pubTimestamp":1713007267,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics is an under-the-radar biotech company that achieved its listing on the Nasdaq through a merger between Catalyst Biosciences and GNI Group.Gyre focuses on developing small-molecule an","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/649303556/image_649303556.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/649303556/image_649303556.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4683596-gyre-therapeutics-under-radar-biotech-shot-at-mash-approval-in-time-stock","is_publish_highlight":false,"gpt_icon":0},{"id":"2426232244","title":"Analysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Phathom Pharmaceuticals (PHAT) and Amylyx Pharmaceuticals Inc (AMLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2426232244","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426232244?lang=en_us&edition=fundamental","pubTime":"2024-04-11 18:30","pubTimestamp":1712831421,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rallybio (RLYB – Research Report), Phathom Pharmaceu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-rallybio-rlyb-phathom-pharmaceuticals-phat-and-amylyx-pharmaceuticals-inc-amlx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-rallybio-rlyb-phathom-pharmaceuticals-phat-and-amylyx-pharmaceuticals-inc-amlx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2425944612","title":"Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2425944612","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2425944612?lang=en_us&edition=fundamental","pubTime":"2024-04-07 20:00","pubTimestamp":1712491200,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (NASDAQ:PHAT), Rhythm Pharmaceuticals (NASDAQ:RYTM), and Vaxcyte (NASDAQ:PCVX) are the most likely takeout targets in the pharma space, according to a Needham analyst.  The thr","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/652879820/image_652879820.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/652879820/image_652879820.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4087726-phathom-pharma-rhythm-vaxcyte-most-likely-takeover-targets-in-pharma-analyst","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.phathompharma.com","stockEarnings":[{"period":"1week","weight":0.0146},{"period":"1month","weight":0.0247},{"period":"3month","weight":0.5719},{"period":"6month","weight":0.4175},{"period":"1year","weight":-0.1747},{"period":"ytd","weight":0.138}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0244},{"period":"3month","weight":0.0496},{"period":"6month","weight":0.1623},{"period":"1year","weight":0.267},{"period":"ytd","weight":0.101}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.023646},{"month":2,"riseRate":0.8,"avgChangeRate":0.124053},{"month":3,"riseRate":0,"avgChangeRate":-0.171034},{"month":4,"riseRate":0.6,"avgChangeRate":0.127165},{"month":5,"riseRate":0.6,"avgChangeRate":-0.005823},{"month":6,"riseRate":0.5,"avgChangeRate":0.032691},{"month":7,"riseRate":0.75,"avgChangeRate":0.02808},{"month":8,"riseRate":0.5,"avgChangeRate":0.021824},{"month":9,"riseRate":0.25,"avgChangeRate":-0.020612},{"month":10,"riseRate":0.25,"avgChangeRate":-0.085031},{"month":11,"riseRate":0.4,"avgChangeRate":-0.074543},{"month":12,"riseRate":0.8,"avgChangeRate":0.103809}],"exchange":"NASDAQ","name":"Phathom Pharmaceuticals","nameEN":"Phathom Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Phathom Pharmaceuticals,PHAT,Phathom Pharmaceuticals股票,Phathom Pharmaceuticals股票老虎,Phathom Pharmaceuticals股票老虎国际,Phathom Pharmaceuticals行情,Phathom Pharmaceuticals股票行情,Phathom Pharmaceuticals股价,Phathom Pharmaceuticals股市,Phathom Pharmaceuticals股票价格,Phathom Pharmaceuticals股票交易,Phathom Pharmaceuticals股票购买,Phathom Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction